Related references
Note: Only part of the references are listed.COVID-19 New mutations raise specter of 'immune escape'
Kai Kupferschmidt
SCIENCE (2021)
Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets
Robert M. Cox et al.
NATURE MICROBIOLOGY (2021)
Human Safety, Tolerability, and Pharmacokinetics of Molnupiravir, a Novel Broad-Spectrum Oral Antiviral Agent with Activity against SARS-CoV-2
Wendy P. Painter et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2021)
The variant gambit: COVID-19's next move
Jessica A. Plante et al.
CELL HOST & MICROBE (2021)
Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence
Ester C. Sabino et al.
LANCET (2021)
SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801
Angela Wahl et al.
NATURE (2021)
Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7
Pengfei Wang et al.
NATURE (2021)
Covid-19: The E484K mutation and the risks it poses
Jacqui Wise
BMJ-BRITISH MEDICAL JOURNAL (2021)
Structure and function of SARS-CoV-2 polymerase
Hauke S. Hillen
CURRENT OPINION IN VIROLOGY (2021)
Comparing infectivity and virulence of emerging SARS-CoV-2 variants in Syrian hamsters
Rana Abdelnabi et al.
EBIOMEDICINE (2021)
A Novel Coronavirus from Patients with Pneumonia in China, 2019
Na Zhu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia
Mart Toots et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
β-D-N4-Hydroxycytidine Is a Potent Anti-alphavirus Compound That Induces a High Level of Mutations in the Viral Genome
Nadya Urakova et al.
JOURNAL OF VIROLOGY (2018)